1476720-95-2

Upstream product

• 1476720-93-0 (2S,5S)-2-[5-(4-bromo-phenyl)-1H-imidazol-2-yl]-5-methyl-piperidine 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 72-18-4 L-valine 
• 1476720-91-8 (2S,5S)-2-[5-(4-bromo-phenyl)-1H-imidazol-2-yl]-5-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 149733-38-0 (S)-6-oxo-piperidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 128726-44-3 (S)-6-oxo-piperidine-2-carboxylic acid ethyl ester 
• 34622-39-4 (2S)-6-oxopipecolic acid 
• 1118-90-7 L-homoglutamic acid 

Downstream Products

• 1476720-97-4 [(S)-2-methyl-1-((2S,5S)-5-methyl-2-{5-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-piperidine-1-carbonyl)-propyl]-carbamic acid methyl ester 

Relevant academic research and scientific papers

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formulas (I) or (II): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.